Alumnium-based Adjuvants Produce Long-lasing Vaccinations

1233 WordsFeb 18, 20185 Pages
1.0 INTRODUCTION Aluminium based adjuvants have been used extensively to induce long lasting protective immunity through vaccination and billions of doses have been administered over the years (Lindblad, 2004). But reported incidences of toxicity and side effects of aluminium have raised concerns regarding their safety in childhood vaccines. These effects include minor local reactions such as pain and erythema, a nodule at the site of injection and systemic reactions which may entail fever, malaise, shivering, general aches and headache (Clements and Griffiths, 2002) and is one of the most common reasons for dropout rates, resulting in incomplete immunisation and hence suceptibility to various diseases (Aguado, 1993). A small proportion of vaccinated people also suffered from delayed onset of diffuse myalgia, chronic fatigue and cognitive dysfunction. In some persons, at site of intra-muscular immunization, a granulomatous lesion called macrophagic myofasciitis (MMF) has also been observed. Clinical symptoms associated with MMF is recently delineated as “autoimmune/inflammatory syndrome induced by adjuvants”(ASIA) (Gherardi and Authier, 2012). Despite of this fact, the choice of adjuvants for human vaccination still reflects a compromise between a requirement for adjuvancity and an acceptable level of side-effects (Clements, 1996). At present, in human vaccinations, aluminium based adjuvants are being used primarily in Diphtheria, Tetanus, Pertussis, Hepatitis B,

    More about Alumnium-based Adjuvants Produce Long-lasing Vaccinations

      Open Document